Abstract
Purpose of review Invasive fungal infections remain a predominant cause of morbidity and mortality in the immunocompromised population. Fungal diagnostics, namely the Platelia Aspergillus enzyme immunoassay (Bio-Rad, Redmond, WA) and the Fungitell 1→3-β-D-glucan assay (Associates of Cape Cod, East Falmouth, MA), are now commercially available to assist clinicians in the early diagnosis of fungal infections. This review highlights the performance characteristics of these tests and introduces the reader to other advances in fungal diagnostics. Recent findings Early diagnosis of invasive aspergillosis in patients with leukemia and hematopoietic stem cell transplants is facilitated by the use of the Platelia Aspergillus enzyme immunoassay. This test may also be useful for monitoring the course of invasive aspergillosis. The Fungitell1→3-β-D-glucan assay can be used for early diagnosis of fungal infections due to multiple different organisms, including certain non-Aspergillus mould infections and invasive candidiasis. Physicians utilizing these fungal diagnostic tests should be aware of important issues regarding test performance. Summary Advances in fungal diagnostics are an important addition to the diagnosis and management of invasive fungal infections. Additional tests such as fungal polymerase chain reaction are on the horizon and are expected to be helpful adjuncts to the diagnosis and management of invasive fungal infections.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
